Ipsen beefs up in oncology, buying US biopharma Epizyme The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its Share X Ipsen beefs up in oncology, buying US biopharma Epizyme https://pharmaphorum.com/news/ipsen-beefs-up-in-oncology-buying-us-biopharma-epizyme/
Novartis bags FDA okay for BRAF-positive tumour combination Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for Share X Novartis bags FDA okay for BRAF-positive tumour combination https://pharmaphorum.com/news/novartis-bags-fda-okay-for-braf-positive-tumour-combination/
Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid Share X Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent https://pharmaphorum.com/news/enanta-lawsuit-claims-pfizers-paxlovid-infringes-its-patent/
Novartis faces threat of early generic of MS drug Gilenya in US Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after Share X Novartis faces threat of early generic of MS drug Gilenya in US https://pharmaphorum.com/news/novartis-faces-threat-of-early-generic-of-ms-drug-gilenya-in-us/
AbbVie files Qulipta for chronic migraine prevention AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to Share X AbbVie files Qulipta for chronic migraine prevention https://pharmaphorum.com/news/abbvie-files-qulipta-for-chronic-migraine-prevention/
AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into Share X AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval https://pharmaphorum.com/news/abbvies-skyrizi-beats-il-23-rivals-to-crohns-disease-approval/
Is Merck planning a $30bn-plus move for Seagen? Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its Share X Is Merck planning a $30bn-plus move for Seagen? https://pharmaphorum.com/news/is-merck-planning-a-30bn-plus-move-for-seagen/
Rumour mill says AstraZeneca may be eyeing a takeover of Mereo AstraZeneca is rumoured to be considering a bid to take control of its longstanding partner Mereo BioPharma, according Share X Rumour mill says AstraZeneca may be eyeing a takeover of Mereo https://pharmaphorum.com/news/rumour-mill-says-astrazeneca-may-be-eyeing-a-takeover-of-mereo/
Mallinckrodt tries again with kidney drug terlipressin Manufacturing problems wreaked havoc with Mallinckrodt’s first attempt to secure FDA approval of its treatment candidate terlipressin for Share X Mallinckrodt tries again with kidney drug terlipressin https://pharmaphorum.com/news/mallinckrodt-tries-again-with-kidney-drug-terlipressin/
Alnylam grabs FDA approval for its second amyloidosis therapy Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Share X Alnylam grabs FDA approval for its second amyloidosis therapy https://pharmaphorum.com/news/alnylam-grabs-fda-approval-for-its-second-amyloidosis-therapy/
Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia Share X Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit https://pharmaphorum.com/news/lillys-olumiant-okayed-in-alopecia-with-pfizer-concert-in-hot-pursuit/
FTC launches probe into pharmacy benefit management sector Longstanding claims that one of the reasons for high drug prices in the US is the actions of Share X FTC launches probe into pharmacy benefit management sector https://pharmaphorum.com/news/ftc-launches-probe-into-pharmacy-benefit-management-sector/
Eversana aims athletes’ mental coaching at pharma sales reps Eversana’s suite of commercialisation tools for pharma companies will soon have a new component – cognitive behavioural training Share X Eversana aims athletes’ mental coaching at pharma sales reps https://pharmaphorum.com/news/eversana-aims-athletes-mental-coaching-at-pharma-sales-reps/
Pfizer will exit GSK consumer health JV after spinout GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next Share X Pfizer will exit GSK consumer health JV after spinout https://pharmaphorum.com/news/pfizer-will-exit-gsk-consumer-health-jv-after-spinout/
SEC accuses former AstraZeneca exec of insider trading The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection Share X SEC accuses former AstraZeneca exec of insider trading https://pharmaphorum.com/news/sec-accuses-former-astrazeneca-exec-of-insider-trading/
GSK bolsters vaccines division with $3.3bn swoop on Affinivax GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is Share X GSK bolsters vaccines division with $3.3bn swoop on Affinivax https://pharmaphorum.com/news/gsk-bolsters-vaccines-division-with-3-3bn-swoop-on-affinivax/
Roche puts pressure on SMA rivals with new FDA approval Roche and PTC Therapeutics’ Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger Share X Roche puts pressure on SMA rivals with new FDA approval https://pharmaphorum.com/news/roche-puts-pressure-on-sma-rivals-with-new-fda-approval/
FDA grants speedy review to Dupixent rare skin disease Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology Share X FDA grants speedy review to Dupixent rare skin disease https://pharmaphorum.com/news/fda-grants-speedy-review-to-dupixent-rare-skin-disease/
